Cantor Fitzgerald Reiterates Overweight on Seelos Therapeutics, Maintains $2 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Seelos Therapeutics (NASDAQ:SEEL) and maintained a $2 price target.
August 22, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Seelos Therapeutics and maintained a $2 price target.
The news is directly about Seelos Therapeutics and is likely to influence investor sentiment. However, as the rating and price target have been maintained, the immediate impact on the stock price may be neutral.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100